{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:51:59Z","timestamp":1791114719151,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["CIBEFP\/2023\/164"],"award-info":[{"award-number":["CIBEFP\/2023\/164"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"DOI":"10.1007\/s40263-026-01340-6","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:09:57Z","timestamp":1790964597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-2592","authenticated-orcid":false,"given":"Juri-Alexander","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Catal\u00e1n-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"von Wrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Novitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Surges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Metternich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Helmstaedter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"1340_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2017.1309025","volume":"18","author":"J-A Witt","year":"2017","unstructured":"Witt J-A, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017;18:1\u20134. https:\/\/doi.org\/10.1080\/14656566.2017.1309025.","journal-title":"Expert Opin Pharmacother"},{"key":"1340_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.yebeh.2013.07.013","volume":"29","author":"J-A Witt","year":"2013","unstructured":"Witt J-A, Elger CE, Helmstaedter C. Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy Behav. 2013;29:141\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2013.07.013.","journal-title":"Epilepsy Behav"},{"key":"1340_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.seizure.2008.11.006","volume":"18","author":"HP Bootsma","year":"2009","unstructured":"Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18:327\u201331. https:\/\/doi.org\/10.1016\/j.seizure.2008.11.006.","journal-title":"Seizure"},{"key":"1340_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1212\/WNL.62.1.23","volume":"62","author":"FG Gilliam","year":"2004","unstructured":"Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62:23\u20137.","journal-title":"Neurology"},{"key":"1340_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4:385\u2013407. https:\/\/doi.org\/10.1177\/1756285611417920.","journal-title":"Ther Adv Neurol Disord"},{"key":"1340_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","volume":"17","author":"DW Loring","year":"2007","unstructured":"Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17:413\u201325. https:\/\/doi.org\/10.1007\/s11065-007-9043-9.","journal-title":"Neuropsychol Rev"},{"key":"1340_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.seizure.2016.02.001","volume":"36","author":"C Helmstaedter","year":"2016","unstructured":"Helmstaedter C, Elger CE, Witt JA. The effect of quantitative and qualitative antiepileptic drug changes on cognitive recovery after epilepsy surgery. Seizure. 2016;36:63\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2016.02.001.","journal-title":"Seizure"},{"key":"1340_CR8","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","volume":"25","author":"J-A Witt","year":"2015","unstructured":"Witt J-A, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. Eur Neuropsychopharmacol. 2015;25:1954\u20139. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.027.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1340_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability. CNS Drugs. 2021;35:609\u201318. https:\/\/doi.org\/10.1007\/s40263-021-00819-8.","journal-title":"CNS Drugs"},{"key":"1340_CR10","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94:e2311\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000009530.","journal-title":"Neurology"},{"key":"1340_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM. Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure. 2023;112:1\u201310. https:\/\/doi.org\/10.1016\/j.seizure.2023.09.006.","journal-title":"Seizure"},{"key":"1340_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70567","volume":"15","author":"M Badr","year":"2025","unstructured":"Badr M, Helmstaedter C, Moskau-Hartmann S, Pukropski J, Witt J, R\u00fcber T, et al. Cenobamate in real-word scenario: results on efficacy, side effects, and retention rate in a single centre retrospective study. Brain Behav. 2025;15:e70567. https:\/\/doi.org\/10.1002\/brb3.70567.","journal-title":"Brain Behav"},{"key":"1340_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320. https:\/\/doi.org\/10.1007\/s40263-020-00759-9.","journal-title":"CNS Drugs"},{"key":"1340_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109605","volume":"151","author":"GL Krauss","year":"2024","unstructured":"Krauss GL, Chung SS, Ferrari L, Stern S, Rosenfeld WE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy Behav. 2024;151:109605. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109605.","journal-title":"Epilepsy Behav"},{"key":"1340_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","volume":"102","author":"E Schuetz","year":"2022","unstructured":"Schuetz E, Wagner K, Metternich B, Papadopoulou G, Kravalis K, Heers M, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2022.10.004.","journal-title":"Seizure"},{"key":"1340_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12857","author":"J Catal\u00e1n-Aguilar","year":"2023","unstructured":"Catal\u00e1n-Aguilar J, Hampel KG, Cano-L\u00f3pez I, Garc\u00e9s M, Lozano-Garc\u00eda A, Tormos-Pons P, et al. Prospective study of cenobamate on cognition, affectivity and quality of life in focal epilepsy. Epilepsia Open. 2023. https:\/\/doi.org\/10.1002\/epi4.12857.","journal-title":"Epilepsia Open"},{"key":"1340_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","volume":"38","author":"PJ Serrano-Castro","year":"2024","unstructured":"Serrano-Castro PJ, Ram\u00edrez-Garc\u00eda T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38:141\u201351. https:\/\/doi.org\/10.1007\/s40263-024-01063-6.","journal-title":"CNS Drugs"},{"key":"1340_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40120-025-00859-y","volume":"15","author":"T Ramirez-Garcia","year":"2026","unstructured":"Ramirez-Garcia T, Cabezudo-Garcia P, Garcia-Martin G, Lopez-Moreno Y, Sanchez-Guijo A, De La Parra J, et al. Long-term impact of cenobamate on cognition in patients with drug-resistant focal epilepsy: outcomes from an exploratory real-world study. Neurol Ther. 2026;15:193\u2013211. https:\/\/doi.org\/10.1007\/s40120-025-00859-y.","journal-title":"Neurol Ther"},{"key":"1340_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/13554794.2024.2366472","volume":"30","author":"J-A Witt","year":"2024","unstructured":"Witt J-A, Moskau-Hartmann S, Olaciregui Dague K, Surges R, Helmstaedter C. Severe memory decline along with unaffected executive functions under 400 mg\/day of cenobamate leading to a collapse in school performance. Neurocase. 2024;30:91\u20136. https:\/\/doi.org\/10.1080\/13554794.2024.2366472.","journal-title":"Neurocase"},{"key":"1340_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","volume":"39","author":"J-A Witt","year":"2025","unstructured":"Witt J-A, Badr M, Surges R, Von Wrede R, Helmstaedter C. The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy. CNS Drugs. 2025;39:893\u2013902. https:\/\/doi.org\/10.1007\/s40263-025-01196-2.","journal-title":"CNS Drugs"},{"key":"1340_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109292","volume":"221","author":"WS Song","year":"2022","unstructured":"Song WS, Cho YS, Oh SP, Yoon SH, Kim YS, Kim MH. Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms. Neuropharmacology. 2022;221:109292. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109292.","journal-title":"Neuropharmacology"},{"key":"1340_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.seizure.2021.12.001","volume":"94","author":"J-A Witt","year":"2022","unstructured":"Witt J, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure. 2022;94:107\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2021.12.001.","journal-title":"Seizure"},{"key":"1340_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110268","volume":"164","author":"KJ Meador","year":"2025","unstructured":"Meador KJ, Seliger J, Le S, Li Y, Razavi B, Falco-Walter J, et al. Cognitive and behavioral effects of perampanel 4 mg daily dose. Epilepsy Behav. 2025;164:110268. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110268.","journal-title":"Epilepsy Behav"},{"key":"1340_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u201382. https:\/\/doi.org\/10.1111\/epi.12550.","journal-title":"Epilepsia"},{"key":"1340_CR25","unstructured":"Helmstaedter C. EpiTrack\u00ae\u2014Ver\u00e4nderungssensitives kognitives Screening zur Beurteilung der Aufmerksamkeit und der Exekutivfunktionen f\u00fcr die Qualit\u00e4ts- und Ergebniskontrolle der Behandlung von Patienten mit Epilepsie [Internet]. Frankfurt: Eisai GmbH; 2019. https:\/\/www.eisai.de\/fachkreise\/neurologie\/service\/#EpiTrack."},{"key":"1340_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.yebeh.2012.09.015","volume":"26","author":"J-A Witt","year":"2013","unstructured":"Witt J-A, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy\u2014approaching the individual patient. Epilepsy Behav. 2013;26:450\u20136. https:\/\/doi.org\/10.1016\/j.yebeh.2012.09.015.","journal-title":"Epilepsy Behav"},{"key":"1340_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.yebeh.2005.08.015","volume":"7","author":"MT Lutz","year":"2005","unstructured":"Lutz MT, Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav. 2005;7:708\u201314. https:\/\/doi.org\/10.1016\/j.yebeh.2005.08.015.","journal-title":"Epilepsy Behav"},{"key":"1340_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.yebeh.2008.07.012","volume":"13","author":"C Helmstaedter","year":"2008","unstructured":"Helmstaedter C, Witt J-A. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav. 2008;13:642\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2008.07.012.","journal-title":"Epilepsy Behav"},{"key":"1340_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yebeh.2010.02.011","volume":"18","author":"C Helmstaedter","year":"2010","unstructured":"Helmstaedter C, Witt J-A. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. Epilepsy Behav. 2010;18:74\u201380. https:\/\/doi.org\/10.1016\/j.yebeh.2010.02.011.","journal-title":"Epilepsy Behav"},{"key":"1340_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.yebeh.2012.11.052","volume":"26","author":"C Helmstaedter","year":"2013","unstructured":"Helmstaedter C, Witt J-A. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy Behav. 2013;26:182\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2012.11.052.","journal-title":"Epilepsy Behav"},{"key":"1340_CR31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/epi.16576","volume":"61","author":"C Meschede","year":"2020","unstructured":"Meschede C, Witt JA, Br\u00f6mling S, Moskau-Hartmann S, Rademacher M, Surges R. Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: a retrospective study using Bayes statistics. Epilepsia. 2020;61:1481\u201390. https:\/\/doi.org\/10.1111\/epi.16576.","journal-title":"Epilepsia"},{"key":"1340_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","volume":"58","author":"C Meschede","year":"2018","unstructured":"Meschede C, Witt J, Rademacher M, Wrede RDV, Elger CE, Helmstaedter C. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure Eur J Epilepsy. 2018;58:141\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2018.04.015.","journal-title":"Seizure Eur J Epilepsy."},{"key":"1340_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2018.09.016","volume":"62","author":"J-A Witt","year":"2018","unstructured":"Witt J-A, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting\u2014preliminary data. Seizure. 2018;62:49\u201354. https:\/\/doi.org\/10.1016\/j.seizure.2018.09.016.","journal-title":"Seizure"},{"key":"1340_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00969-3","author":"J-A Witt","year":"2022","unstructured":"Witt J-A, Widman G, Hansen N, von Wrede R, Elger CE, Helmstaedter C. Evaluation of a rapid topiramate titration scheme for the early detection of cognitive side effects. CNS Drugs. 2022. https:\/\/doi.org\/10.1007\/s40263-022-00969-3.","journal-title":"CNS Drugs"},{"key":"1340_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3758\/s13423-017-1317-5","volume":"25","author":"A Etz","year":"2018","unstructured":"Etz A, Gronau QF, Dablander F, Edelsbrunner PA, Baribault B. How to become a Bayesian in eight easy steps: an annotated reading list. Psychon Bull Rev. 2018;25:219\u201334. https:\/\/doi.org\/10.3758\/s13423-017-1317-5.","journal-title":"Psychon Bull Rev"},{"key":"1340_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16720","author":"J-A Witt","year":"2020","unstructured":"Witt J-A, Nass RD, Baumgartner T, von Wrede R, Elger CE, Surges R, et al. Does the accumulated antiepileptic drug load in chronic epilepsy reflect disease severity? Epilepsia. 2020. https:\/\/doi.org\/10.1111\/epi.16720.","journal-title":"Epilepsia"},{"key":"1340_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109156","volume":"142","author":"M Osborn","year":"2023","unstructured":"Osborn M, Abou-Khalil B. The cenobamate\u2013clobazam interaction\u2014evidence of synergy in addition to pharmacokinetic interaction. Epilepsy Behav. 2023;142:109156. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109156.","journal-title":"Epilepsy Behav"},{"key":"1340_CR38","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","volume":"11","author":"MC Smith","year":"2022","unstructured":"Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705\u201320. https:\/\/doi.org\/10.1007\/s40120-022-00400-5.","journal-title":"Neurol Ther."},{"key":"1340_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/13554794.2022.2032187","volume":"28","author":"J-A Witt","year":"2022","unstructured":"Witt J-A, Rademacher M, von Wrede R, Surges R, Helmstaedter C. Cognitive reawakening and improved quality of life achieved after discontinuing 16 years of anti-seizure treatment with topiramate. Neurocase. 2022;28:102\u20136. https:\/\/doi.org\/10.1080\/13554794.2022.2032187.","journal-title":"Neurocase"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01340-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:01:48Z","timestamp":1791111708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":39,"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01340-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAW reports personal fees from Eisai GmbH, UCB Pharma GmbH, Jazz Pharmaceuticals Germany GmbH, and Angelini Pharma Deutschland GmbH, outside the submitted work. RS has received personal fees as speaker or for serving on advisory boards from Angelini, Arvelle, Bial, Desitin, Eisai, Jazz Pharmaceuticals Germany GmbH, Janssen-Cilag GmbH, LivaNova, LivAssured B.V., Novartis, Precisis GmbH, Rapport Therapeutics, UCB Pharma, UNEEG, and Zogenix, outside the submitted work. RvW reports fees as speaker or for serving on advisory boards from Angelini, Arvelle, personal fees from Apocare, personal fees from Eisai, other from GW pharma, personal fees from UCB, personal fees from Desitin, outside the submitted work. CH reports honoraria for speeches, webinars, counselling etc., from UCB, Eisai, Angelini, GW, Precisis, Jazz Pharma, honoraria for expert testimonies, as well as license fees from UCB and Eisai, outside the submitted work. VV has received honoraria and\/or research funds from Adium, Angelini Pharma, Bial, Eisai, Jazz Pharmaceuticals, Neuraxpharm, Novartis, Rapport, Takeda, UCB Pharma and Xenon, outside the submitted work. MG has received honoraria from Angelini Pharma, Eisai, Jazz Pharmaceuticals, and UCB Pharma, outside the submitted work. YN received financial support from Eisai and Angelini outside of the present work. These activities were not related to the drafting and the explicit content of this manuscript. ES has received honoraria for one lecture and support for attending a congress from Angelini Pharma, outside of the present work. BM, JCA, KGH, and KW have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multicentre retrospective analysis used fully anonymised patient-level data previously collected at three participating centres. Data at each site were gathered under the terms of local ethics committee approvals (in Valencia the ethics committee of the Hospital Universitario y Polit\u00e9cnico La Fe, in Freiburg the ethics committee of the University Medical Centre Freiburg) or under the governance of an established registry (local ASM registry approved by the Ethics commission of the Medical Faculty at the University of Bonn (No. 130\/19)), and no new data collection or direct patient contact took place for the present analysis.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this retrospective analysis, all datasets were de-identified before transfer and cannot be used to re-identify individuals; therefore, per applicable national and institutional rules, written informed consent for this secondary analysis were not required. All participating centres of this multicentre study adhered to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The dataset analysed during the current study is not publicly available. Data will be made available on reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI, in the form of large language models (LLMs), was used to refine the language of parts of the manuscript. Specifically, Perplexity (\n                      \n                      ) was used for language polishing and phrasing suggestions. The authors reviewed, edited, and take full responsibility for the final content.","order":7,"name":"Ethics","label":"Artificial Intelligence (AI) Use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CH and JAW conceptualised the study. All authors were involved in the acquisition of clinical or neuropsychological data. JAW performed the data analysis and prepared the first draft of the manuscript. All authors revised the manuscript for intellectual content, approved the final version of the manuscript and are accountable for their work.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}